Why the study?
Translational medicine has advanced ECMO technology and patient outcomes, but challenges such as patient heterogeneity and regulatory hurdles persist.
Answers are grounded in this paper and cite their sources.
Translational medicine has driven critical innovations in ECMO circuit design, anticoagulation, and predictive modeling, though further collaborative research is needed to overcome clinical and regulatory barriers.
Extracorporeal membrane oxygenation (ECMO) serves as a critical intervention for patients experiencing severe cardiac or respiratory failure.Translational medicine, which bridges laboratory research and clinical practice, has significantly advanced ECMO technology and patient outcomes.This narrative review examines how translational research has influenced ECMO development, including innovations in biomaterials, anticoagulation strategies, and computational modeling.Despite these advancements, challenges such as patient heterogeneity and regulatory hurdles persist.Collaborative efforts between researchers, clinicians, and industry remain essential to further refine ECMO therapy and improve survival rates while minimizing complications.
No takes yet. Share an insight, caveat, or question.
Oza et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: